UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Clinical cancer research, 2017-04, Vol.23 (8), p.1920-1928

2017

Link zum Volltext

Verfügbarkeit prüfen

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

Scientific reports, 2017-08, Vol.7 (1), p.7952-10, Article 7952

2017

Link zum Volltext

Verfügbarkeit prüfen

Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer

Cancer medicine (Malden, MA), 2023-02, Vol.12 (3), p.3172-3175

2023

Link zum Volltext

Verfügbarkeit prüfen

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2178-2184

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

Investigational new drugs, 2021-08, Vol.39 (4), p.1089-1098

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Investigational new drugs, 2020-04, Vol.38 (2), p.402-409

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2009-12, Vol.15 (23), p.7421-7428

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer

Investigational new drugs, 2021-02, Vol.39 (1), p.193-201

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

The European respiratory journal, 2018-01, Vol.51 (1), p.1701737-1701737

2018

Link zum Volltext

Verfügbarkeit prüfen

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

PloS one, 2012-11, Vol.7 (11), p.e47020-e47020

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2429-2435

2009

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan‐cancer analysis

Molecular oncology, 2022-04, Vol.16 (7), p.1451-1473

2022

Link zum Volltext

Verfügbarkeit prüfen

Patterns of progression in patients treated for immuno-oncology antibodies combination

Cancer Immunology, Immunotherapy, 2021-01, Vol.70 (1), p.221-232

2021

Link zum Volltext

Verfügbarkeit prüfen

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.337-337, Article 337

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting continued androgen receptor signaling in prostate cancer

Clinical cancer research, 2011-06, Vol.17 (12), p.3876-3883

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Journal of experimental & clinical cancer research, 2022-07, Vol.41 (1), p.1-217, Article 217

2022

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?

Frontiers in immunology, 2021-11, Vol.12, p.745146

2021

Link zum Volltext

Verfügbarkeit prüfen

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

Cancers, 2022-10, Vol.14 (20), p.5078

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Journal for immunotherapy of cancer, 2017-04, Vol.5 (1), p.31-31, Article 31

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e003697

2022

Link zum Volltext

Verfügbarkeit prüfen

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Translational oncology, 2021-02, Vol.14 (2), p.100984-100984, Article 100984

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 609

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(567)
Mit Volltextzugriff
(551)

Publikationsform

Sprache

Englisch
(506)
Französisch
(108)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(300)
Life Sciences & Biomedicine
(289)
Humans
(243)
Oncology
(240)
Male
(154)
Middle Aged
(120)
Female
(114)
Aged
(96)
Cancer
(90)
Tumors
(85)
Adult
(76)
Life Sciences
(72)
Patients
(69)
Antineoplastic Agents - Therapeutic Use
(49)
Treatment Outcome
(49)
Prognosis
(47)
Immunotherapy
(46)
Aged, 80 And Over
(45)
Neoplasms - Drug Therapy
(43)
Clinical Trials
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan‐cancer analysis

Patterns of progression in patients treated for immuno-oncology antibodies combination

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Targeting continued androgen receptor signaling in prostate cancer

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Suchergebnisse filtern